Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, which may enhance the attractiveness of the warrant for investors [3]. Group 1: Warrant Transaction Background - On November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital for a warrant exercisable into up to 2,000,000 newly issued ordinary shares for an aggregate purchase price of US$100,000 [2]. - The warrant was issued on December 4, 2025, and can be exercised for cash for 90 days from the issuance date, after which a cashless exercise will occur if not exercised [2]. Group 2: Amended Terms - The Warrant Amendment, effective December 16, 2025, reduces the exercise price from US$6.00 to US$4.00 per share [3]. - The minimum closing price required to trigger a "Forced Exercise" has been reduced from US$7.50 to US$6.00 [3]. Group 3: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [4]. - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the growing longevity sector [4]. - EUDA is positioned to transform regional healthcare from reactive treatment to proactive, longevity-focused care [4].

Core Viewpoint - EUDA Health Holdings Limited has entered into a securities purchase agreement with Streeterville Capital for a convertible warrant, aiming to strengthen its capital position and support growth strategies in the non-invasive healthcare market in Asia [1][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider focusing on Singapore, Malaysia, and China, with a mission to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care [5]. - The company targets the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [5]. Financial Details - The securities purchase agreement involves the sale of a convertible warrant for an aggregate purchase price of US$100,000, which is exercisable for up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share [1][3]. - The warrant can be exercised for cash within a 90-day period, with conditions allowing the company to require Streeterville Capital to exercise the warrant under specific trading volume and price conditions [3]. Strategic Intent - The CEO of EUDA emphasized that the warrant financing provides flexibility to invest in high-return initiatives, including new centers, partnerships, and technology, to expand the company's footprint in Asia's non-invasive healthcare market [4].